5th mRNA-Based Therapeutics Summit Europe

The 5th mRNA-Based Therapeutics Summit Europe is the leading European industry-focused forum dedicated to accelerating the safe, scalable, and clinically impactful development of messenger RNA (mRNA) medicines. Returning for its fifth year in Berlin from 27 – 29 January 2026, this essential meeting unites 170+ senior leaders across R&D, CMC (Chemistry, Manufacturing, and Controls), Regulatory Affairs, Clinical Development, and Business Strategy from Europe and around the globe.

The summit provides a comprehensive, end-to-end program, featuring never-before-seen preclinical and clinical data from industry trailblazers such as Moderna, AstraZeneca, and BioNTech. The agenda is meticulously structured to address the field’s most pressing challenges and opportunities: broadening mRNA’s scope beyond infectious disease vaccines into oncology, rare diseases, and beyond; overcoming the key bottleneck of targeted and tissue-specific delivery; and resolving complex CMC and stability hurdles for next-generation modalities like self-amplifying RNA (saRNA) and circular RNA (circRNA).

New for 2026 is a dedicated Gene Editing Focus Day, highlighting how mRNA technology enables safer, transient editing strategies and exploring its translational potential in regenerative indications. Attendees will gain actionable, exclusive insights on critical topics including advanced LNP and polymeric delivery systems, manufacturing scale-up, and the integration of AI into mRNA design.

Additionally, the summit offers high-profile investor sessions, providing candid perspectives on the clinical milestones, strategic proof points, and investment signals necessary to make an mRNA platform fundable in today’s competitive landscape. By fostering collaboration and sharing best practices, the 5th mRNA-Based Therapeutics Summit Europe is the premier platform to de-risk development pipelines and ensure the next generation of revolutionary mRNA medicines successfully reach patients.

To know more visit: https://ter.li/t3lsz2